Developer docs
API playgroundTry for free, no card

Search company profiles

Mid Atlantic Bio Angels

Full company profile

uuid0009alb

Namestring
Mid Atlantic Bio Angels
Websiteurl
bioangels.net
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Mid Atlantic Bio Angels is a New York-based angel investment group founded in 2012 that focuses on funding early-stage life science and biotechnology companies. The group operates a community-led model, sourcing deals through industry networks, professional referrals, and co-investor relationships within the biotech investment community. Its core activity centers on syndicated angel rounds, typically with total deal sizes under $30 million, providing both capital and sector-specific due diligence expertise to portfolio companies. The organization serves two primary constituencies: early-stage life science and biotech startups seeking capital and specialized guidance, and angel investors seeking curated exposure to vetted biotech deal flow.

The group's investment approach emphasizes strong management teams, realistic market assessments, clear milestones, and viable exit pathways, with an explicit preference for acquisition exits over IPOs. Mid Atlantic Bio Angels generates returns through carried interest on successful investments and exit proceeds from portfolio companies, rather than through management fees or a technology product offering. The company is led by founder Yaniv Sneor and co-founder Stephen Goodman, whose domain expertise in life science due diligence and commercial alignment is central to the group's positioning as a specialist in a sector where rigorous evaluation is critical. No proprietary technology platform, software product, or AI-driven tooling is disclosed.

The competitive position of Mid Atlantic Bio Angels rests on domain specialization and network effects within the biotech investment community. It addresses the capital gap for early-stage life science companies that struggle to secure traditional venture funding, while providing investors with curated deal flow and rigorous due diligence in a high-risk, specialized sector. The group has maintained continuous operation since founding, with active deal participation as recently as April 2026. There is no disclosed institutional backing, parent company, or external funding; the group operates as an independent angel collective.

Short descriptiontext

Mid Atlantic Bio Angels is a New York-based angel investment group founded in 2012 that funds early-stage life science and biotechnology companies through syndicated rounds typically under $30 million, providing capital and specialized due diligence expertise to biotech startups and curated deal flow to angel investors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
angel investing, life science funding, biotech venture capital, early-stage investment, syndicated funding rounds
Industry2 codes
PRIMARYFSANAAAI
Micro-VC & Angel Funds
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code1 code
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Angel Investment Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment returns and carried interest
TypeProfessional Services
Description

As an angel investment group, Mid-Atlantic Bio Angels generates returns through carried interest on successful investments and exit proceeds from portfolio companies. The group participates in syndicated investment rounds with typical deal sizes under $30 million total investment.

biospace.com
Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Mid Atlantic Bio Angels is a life science angel investment group that deploys early-stage capital into new and emerging biotech and life science companies through syndicated investment rounds, typically with total deal sizes under $30 million. The group pairs funding with specialized due diligence expertise, milestone-based investment criteria, and guidance on exit pathways, with a stated preference for acquisition exits over IPOs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mid Atlantic Bio Angels is a life science angel investment group that provides funding and advisory support to early-stage biotech companies. The organization does not appear to offer a software product, platform, or technology service offering based on available source data. The company focuses on connecting biotech entrepreneurs with angel investors and conducting due diligence on potential investments.

Product and service2 records
1Early-stage life science angel investment
CategoryAngel Investment Services
Description

Angel investment funding for early-stage biotech and life science companies, deployed through syndicated rounds typically totaling under $30 million, paired with specialized due diligence, milestone-based investment criteria, and exit pathway guidance with a preference for acquisition exits. Targeted at founders and management teams of early-stage life science and biotech startups.

2Specialized life science due diligence
CategoryDue Diligence Services
Description

Domain-specific due diligence tailored to evaluating early-stage therapeutic and diagnostic opportunities, providing investors and portfolio companies with rigorous assessment of management teams, market viability, milestones, and exit pathways.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest and most active angel investor groups in the U.S. focused exclusively on life-science and biotech deals. Directly comparable to Mid-Atlantic Bio Angels in target sector, due-diligence approach, and syndicated angel structure.

TypeRegional player
Description

Established New York–based angel network investing across sectors including life sciences. Comparable as a regionally anchored angel collective operating in the same geographic market as Mid-Atlantic Bio Angels.

TypeDirect peer
Description

Silicon Valley–based angel group with active life-science and healthcare deal flow. Comparable in operating model (syndicated angel investing with domain-focused sub-groups) and in serving as a feeder into larger biotech rounds.

TypeDirect peer
Description

Large global angel investor network with chapters across multiple regions including the U.S. East Coast. Comparable in syndicated angel structure and in active life-science deal flow, with a similar member-driven deal-sourcing model.

TypeDirect peer
Description

One of the largest U.S. angel networks, with healthcare and biotech investments alongside tech. Comparable as a large syndicated angel platform with formal due-diligence processes and a chapter-based structure.

TypeDirect peer
Description

Angel investment group with a focus on women-led companies, including a meaningful life-science and healthcare portfolio. Comparable in syndicated angel structure, New York presence, and sector-aware due diligence.

TypeBroad incumbent
Description

Industry association for U.S. angel groups. Comparable as a broader ecosystem participant that supports the operating environment Mid-Atlantic Bio Angels operates in, rather than a direct investing peer.

TypeEmerging player
Description

Large biotech-focused venture firm that frequently co-invests with or follows angel-led rounds. Comparable as a sector specialist that overlaps in target deal type (early-stage life sciences) but operates at materially larger check sizes.

TypeEmerging player
Description

Biotech-focused early-stage venture firm that often enters at the seed/Series A stage. Comparable in target stage and sector but with a much larger fund and institutional LP base.

10BioEnterprise
TypeRegional player
Description

Regional life-science commercialization and investor-relations organization. Comparable as an ecosystem player supporting biotech deal flow in the broader U.S. Northeast/Midwest region.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment27 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mid Atlantic Bio Angels

Angel Investment Servicesbioangels.net

Mid Atlantic Bio Angels is a New York-based angel investment group founded in 2012 that funds early-stage life science and biotechnology companies through syndicated rounds typically under $30 million, providing capital and specialized due diligence expertise to biotech startups and curated deal flow to angel investors.

What Mid Atlantic Bio Angels does

Mid Atlantic Bio Angels is a New York-based angel investment group founded in 2012 that focuses on funding early-stage life science and biotechnology companies. The group operates a community-led model, sourcing deals through industry networks, professional referrals, and co-investor relationships within the biotech investment community. Its core activity centers on syndicated angel rounds, typically with total deal sizes under $30 million, providing both capital and sector-specific due diligence expertise to portfolio companies. The organization serves two primary constituencies: early-stage life science and biotech startups seeking capital and specialized guidance, and angel investors seeking curated exposure to vetted biotech deal flow.

The group's investment approach emphasizes strong management teams, realistic market assessments, clear milestones, and viable exit pathways, with an explicit preference for acquisition exits over IPOs. Mid Atlantic Bio Angels generates returns through carried interest on successful investments and exit proceeds from portfolio companies, rather than through management fees or a technology product offering. The company is led by founder Yaniv Sneor and co-founder Stephen Goodman, whose domain expertise in life science due diligence and commercial alignment is central to the group's positioning as a specialist in a sector where rigorous evaluation is critical. No proprietary technology platform, software product, or AI-driven tooling is disclosed.

The competitive position of Mid Atlantic Bio Angels rests on domain specialization and network effects within the biotech investment community. It addresses the capital gap for early-stage life science companies that struggle to secure traditional venture funding, while providing investors with curated deal flow and rigorous due diligence in a high-risk, specialized sector. The group has maintained continuous operation since founding, with active deal participation as recently as April 2026. There is no disclosed institutional backing, parent company, or external funding; the group operates as an independent angel collective.

Mid Atlantic Bio Angels firmographics

Firmographics
Name
Mid Atlantic Bio Angels
Website
https://bioangels.net
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Mid Atlantic Bio Angels is a New York-based angel investment group founded in 2012 that funds early-stage life science and biotechnology companies through syndicated rounds typically under $30 million, providing capital and specialized due diligence expertise to biotech startups and curated deal flow to angel investors.
Ownership category
akta.pro rank

Mid Atlantic Bio Angels industry classification

Industry
Product category
Angel Investment Services
NAICS
Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAI
Micro-VC & Angel Funds
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Angel investing
  • Life science funding
  • Biotech venture capital
  • Early-stage investment
  • Syndicated funding rounds

Where Mid Atlantic Bio Angels is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Mid Atlantic Bio Angels business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Investment returns and carried interest: As an angel investment group, Mid-Atlantic Bio Angels generates returns through carried interest on successful investments and exit proceeds from portfolio companies. The group participates in syndicated investment rounds with typical deal sizes under $30 million total investment.

Go-to-market motion1 record

Mid Atlantic Bio Angels product offering

Product offering

Core offering

Mid Atlantic Bio Angels is a life science angel investment group that deploys early-stage capital into new and emerging biotech and life science companies through syndicated investment rounds, typically with total deal sizes under $30 million. The group pairs funding with specialized due diligence expertise, milestone-based investment criteria, and guidance on exit pathways, with a stated preference for acquisition exits over IPOs.

Product overview

Mid Atlantic Bio Angels is a life science angel investment group that provides funding and advisory support to early-stage biotech companies. The organization does not appear to offer a software product, platform, or technology service offering based on available source data. The company focuses on connecting biotech entrepreneurs with angel investors and conducting due diligence on potential investments.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early-stage life science angel investment Angel investment funding for early-stage biotech and life science companies, deployed through syndicated rounds typically totaling under $30 million, paired with specialized due diligence, milestone-based investment criteria, and exit pathway guidance with a preference for acquisition exits. Targeted at founders and management teams of early-stage life science and biotech startups.
  • Specialized life science due diligence Domain-specific due diligence tailored to evaluating early-stage therapeutic and diagnostic opportunities, providing investors and portfolio companies with rigorous assessment of management teams, market viability, milestones, and exit pathways.

Companies that use Mid Atlantic Bio Angels

Customer profile

Segments2 records

Ideal customer profiles2 records

Mid Atlantic Bio Angels technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Mid Atlantic Bio Angels partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights2 records

Mid Atlantic Bio Angels competitors and assessment

Company assessment

Direct peers

  • Life Science Angels: One of the largest and most active angel investor groups in the U.S. focused exclusively on life-science and biotech deals. Directly comparable to Mid-Atlantic Bio Angels in target sector, due-diligence approach, and syndicated angel structure.
  • Band of Angels: Silicon Valley–based angel group with active life-science and healthcare deal flow. Comparable in operating model (syndicated angel investing with domain-focused sub-groups) and in serving as a feeder into larger biotech rounds.
  • Keiretsu Forum: Large global angel investor network with chapters across multiple regions including the U.S. East Coast. Comparable in syndicated angel structure and in active life-science deal flow, with a similar member-driven deal-sourcing model.
  • Tech Coast Angels: One of the largest U.S. angel networks, with healthcare and biotech investments alongside tech. Comparable as a large syndicated angel platform with formal due-diligence processes and a chapter-based structure.
  • Golden Seeds: Angel investment group with a focus on women-led companies, including a meaningful life-science and healthcare portfolio. Comparable in syndicated angel structure, New York presence, and sector-aware due diligence.

Regional players

  • New York Angels: Established New York–based angel network investing across sectors including life sciences. Comparable as a regionally anchored angel collective operating in the same geographic market as Mid-Atlantic Bio Angels.
  • BioEnterprise: Regional life-science commercialization and investor-relations organization. Comparable as an ecosystem player supporting biotech deal flow in the broader U.S. Northeast/Midwest region.

Broad incumbents

  • Angel Capital Association: Industry association for U.S. angel groups. Comparable as a broader ecosystem participant that supports the operating environment Mid-Atlantic Bio Angels operates in, rather than a direct investing peer.

Emerging players

  • ARCH Venture Partners: Large biotech-focused venture firm that frequently co-invests with or follows angel-led rounds. Comparable as a sector specialist that overlaps in target deal type (early-stage life sciences) but operates at materially larger check sizes.
  • Atlas Venture: Biotech-focused early-stage venture firm that often enters at the seed/Series A stage. Comparable in target stage and sector but with a much larger fund and institutional LP base.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Mid Atlantic Bio Angels social profiles

Digital presence

Mid Atlantic Bio Angels financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mid Atlantic Bio Angels leadership team

Management profile

Number of profiles

Profiles2 records

Mid Atlantic Bio Angels funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mid Atlantic Bio Angels M&A and investment

M&A and investment

M&A

Investments27 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mid Atlantic Bio Angels

What does Mid Atlantic Bio Angels do?

Mid Atlantic Bio Angels is a life science angel investment group that deploys early-stage capital into new and emerging biotech and life science companies through syndicated investment rounds, typically with total deal sizes under $30 million. The group pairs funding with specialized due diligence expertise, milestone-based investment criteria, and guidance on exit pathways, with a stated preference for acquisition exits over IPOs.

Is Mid Atlantic Bio Angels a public or private company?

Mid Atlantic Bio Angels is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Mid Atlantic Bio Angels founded?

Mid Atlantic Bio Angels was founded in 2012. It employs 11 to 50 people.

Where is Mid Atlantic Bio Angels based?

Mid Atlantic Bio Angels is headquartered in New York, United States, in the North America region.

How does Mid Atlantic Bio Angels make money?

One revenue line is on record: investment returns and carried interest.

Who are Mid Atlantic Bio Angels's main competitors?

Direct peers on record are Life Science Angels, Band of Angels, Keiretsu Forum, Tech Coast Angels and Golden Seeds. Regional players are New York Angels and BioEnterprise. Angel Capital Association is listed as a broad incumbent. Emerging players are ARCH Venture Partners and Atlas Venture.

Does Mid Atlantic Bio Angels have an API?

No public API is recorded for Mid Atlantic Bio Angels.

What industry is Mid Atlantic Bio Angels in?

Mid Atlantic Bio Angels's product category is Angel Investment Services. Its primary akta.pro industry code is FSANAAAI, Micro-VC & Angel Funds, with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 525990 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceWhat makes life science angel investment work?This is a podcast episode of Denatured featuring Yaniv Sneor, founder of Mid Atlantic Bio Angels, and Alex Pederson, an investor at Mid Atlantic Bio Angels and partner at Alloy Bio Consulting, discussing the value of life science-focused angel investing and how such groups evaluate opportunities.BioSpaceBiotech angels lean into deeper diligence and disciplined early betsAngel investors in the biotech sector are adopting stricter investment criteria, focusing on strong management teams, realistic market assessments, clear milestones, and viable exit pathways rather than inflated market projections. Industry experts like Mid-Atlantic Bio Angels founder Yaniv Sneor and investor Alex Pederson emphasize that life science deals require specialized due diligence, commercial alignment, and preference for acquisition exits over IPOs. The trend reflects broader discipline in early-stage biotech funding, with angels typically seeking total investments under $30 million across syndicated rounds before exit.EIN PresswireMid Atlantic Bio Angels Invests in Veterinary Biotech Company Hilltop BioMid Atlantic Bio Angels (MABA) has invested in veterinary biotech company Hilltop Bio, marking MABA's first engagement with a firm in the veterinary sector. The investment involves individual investors, MABA’s internal Pool III, and its Sidecar Fund II, supporting Hilltop Bio's development of regenerative therapies for inflammatory diseases in animals.EIN PresswireMABA Invests in 3D Shape Sensing TechnologyMid Atlantic Bio Angels (MABA) has invested in The Shape Sensing Company (TSSC), focusing on advancing 3D shape sensing technology for surgical navigation. This investment aims to enhance the effectiveness and safety of surgical procedures, ultimately improving patient outcomes. MABA's support highlights its commitment to fostering promising health care startups.GlobeNewswireMid Atlantic Bio Angels Members and Its Closed-End Investment Pool II Makes Investment in Healionics CorporationMid Atlantic Bio Angels' closed-end investment pool II invested in Healionics Corporation, a Seattle-based company developing vascular grafts. The investment supports Healionics' first human study of its STARgraft, which has shown better reliability than on-market devices in preclinical studies.GlobeNewswireMid Atlantic Bio Angels Introduces “Sidecar Fund” for Non-Members to Participate in MABA InvestmentsMid Atlantic Bio Angels launched a sidecar fund for accredited non-members to co-invest with members. The fund has a $100,000 minimum, $500,000 maximum per investor, and a $5 million total cap, investing automatically in a fixed ratio to member investments.GlobeNewswireMid Atlantic Bio Angels Invests in Salarius PharmaceuticalsMid Atlantic Bio Angels invested in Houston-based Salarius Pharmaceuticals, which develops epigenetic cancer treatments. The company's lead compound, Seclidemstat, targets Ewing sarcoma, and Salarius received a $18.7 million CPRIT award. The investment validates the company's science and strategy.GlobeNewswireMid Atlantic Bio Angels Initiates Second Investment Pool and Makes Inaugural Investment in POP Medical Solutions, Ltd.Mid Atlantic Bio Angels launched its second closed-end investment pool, Pool II, and made its first investment in Israel-based POP Medical Solutions, which develops NeuGuide for pelvic organ prolapse. The $3M Round A financing will fund a post-marketing study, CE Mark certification, and US commercial launch in early 2019.GlobeNewswireGroup K Diagnostics Wins Mid Atlantic Bio Angels’ “Best of the Best” at 1st Pitch Life Science CompetitionGroup K Diagnostics was named Best of the Best at Mid-Atlantic Bio Angels' 1st Pitch Life Science event on December 13, 2017. The Philadelphia-based company develops a paper-based microfluidic point-of-care diagnostic platform, initially for liver function, with 12 tests in production and over 60 in the pipeline.GlobeNewswireMid Atlantic Bio Angels Invests in Elysium TherapeuticsMid Atlantic Bio Angels made its ninth investment in Elysium Therapeutics, a San Ramon, CA-based company developing O2P opioid pain relievers that prevent oral misuse and fatal overdose. The technology automatically limits opioid levels in the bloodstream, and Elysium has already demonstrated proof-of-concept following a National Institute on Drug Abuse SBIR grant.